Companies / ANR

ANATARA LIFESCIENCES LTD

ASX:ANRPharmaceuticals, Biotechnology & Life Sciences
316.0M shares on issueASX (delayed) · as of 28 July 2026$0.010price · delayed$3.5Mmarket cap · indicative
D
Dilution grade

Runway under 2 quarters; share count grew 64% in 24 months; 2 cash raises in 24 months

Cash runway0.8 quarters of funding
Share-count growth (24m)63.8%
Raise cadence (24m)2 cash raises
Options & rights overhang3.5% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

ANATARA LIFESCIENCES LTD's ordinary share count grew 63.8% between July 2024 and February 2026, to 316M shares. The company raised capital twice in that 24-month window for total disclosed proceeds of A$2.2M, most recently A$1.2M in September 2025. Options and rights on issue could convert into 11M new shares, equal to 3.5% of the current share count, with the nearest expiry in May 2027 and 0% of current shares in the money. At the March 2026 quarter the company reported A$275K in available cash, covering about 0.8 quarters at the recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
3.5%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
0.8 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 316.0M per ASX (delayed) (28 July 2026).
230.6M261.9M293.3MDec 24Sept 25July 26Cash raise · 26 Sept 2025

Cash runway

0.8 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$275k available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
25 Feb 20262A · quoted issueANR : ORDINARY FULLY PAID316.0MAppendix 2A
11 Dec 20253H · cancellationANR : ORDINARY FULLY PAID313.6MAppendix 3H
26 Nov 20253G · unquotedANR : ORDINARY FULLY PAID247.2MAppendix 3G
26 Nov 20252A · quoted issueANR : ORDINARY FULLY PAID313.6MAppendix 2A
25 Nov 20253H · cancellationANR : ORDINARY FULLY PAID247.2MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

2 cash raises in the last 24 months · 1 in the last 12 months

$1.2M
Capital raise
26 Sept 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

3.5%
Total overhang · of current shares
0.0%
In the money · at current price
11.0M
Potential new shares
May 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
11 Dec 2025Dr David BrookesSell7.0M175k—3Y notice
11 Dec 2025John MichailidisSell1.3M——3Y notice
11 Dec 2025Dirk van DisselSell6.1M850k—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

29 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
25 Feb 2026Application for quotation of securities - ANR
25 Feb 2026Conversion of Performance Rights
25 Feb 2026$PAppendix 4D & Half Year Report 31 December 2025
18 Feb 2026$PCompany Update
29 Jan 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
16 Dec 2025$PCompany Update
11 Dec 2025Change of Director Interest Notices x 3
11 Dec 2025Notification of cessation of securities - ANR
27 Nov 2025Change of Director Interest Notices
26 Nov 2025Notification regarding unquoted securities - ANR
26 Nov 2025Application for quotation of securities - ANR
26 Nov 2025Issue of Tranche 2 Placement Shares
25 Nov 2025Notification of cessation of securities - ANR
20 Nov 2025Results of Meeting
19 Nov 20252025 AGM Presentation
19 Nov 2025Chair's Address to Shareholders
14 Nov 2025Notification of cessation of securities - ANR
22 Oct 2025$PQuarterly Activities/Appendix 4C Cash Flow Report
16 Oct 2025Notice of Annual General Meeting/Proxy Form

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.